Dr. Manouchehr Hessabi
← All writing
8 min readenvironment · PFAS · children's health · exposure assessment

PFAS and children: what the evidence shows and cannot yet say

PFAS forever chemicals and human health: what research links to PFOA and PFOS in children, how strong the evidence is, and what a blood test can tell.

By Manouchehr Hessabi, MD, MPH

Nearly everyone in the United States has been exposed to PFAS, but only a few of these thousands of chemicals have been studied for health effects. For those few, research shows associations with outcomes such as higher cholesterol, small decreases in birth weight, and lower antibody response to some vaccines, while the evidence on causation and individual risk remains limited. A PFAS blood test can show exposure, but it cannot say whether a child will become ill.

What are PFAS, and why are they called forever chemicals?

Per- and polyfluoroalkyl substances, or PFAS, are a family of thousands of synthetic chemicals used to reduce friction and to resist oil, water, and stains. They persist in the environment and, for some compounds, in the body for years, which is where the nickname "forever chemicals" comes from. According to the US Agency for Toxic Substances and Disease Registry (ATSDR), nearly all people in the United States have been exposed to PFAS, yet relatively few of the thousands of compounds have been studied for their effects on health (ATSDR, PFAS Information for Clinicians, updated January 18, 2024).

That last point shapes everything that follows. Most of what is known comes from a handful of well-studied compounds:

  • PFOA, perfluorooctanoic acid
  • PFOS, perfluorooctane sulfonic acid
  • PFHxS, perfluorohexane sulfonic acid
  • PFNA, perfluorononanoic acid
  • PFDA, perfluorodecanoic acid

Among the PFAS that have been studied, ATSDR notes that they are absorbed in the intestines and lungs, bind to proteins in blood and tissue, are mostly not metabolized, and have half-lives ranging from a few days to more than eight years. A half-life is the time it takes for the body to clear half of a given amount. A compound with a half-life measured in years can reflect exposures that happened long ago.

How are children exposed?

ATSDR describes ingestion of PFAS in water and food as a main route of exposure for the general population, with dust and residue from PFAS-containing products as another. Communities with contaminated water or food are often near facilities that manufactured, used, or handled PFAS (ATSDR, 2024).

For children specifically, ATSDR lists several routes:

  • Formula mixed with PFAS-containing water
  • Breastmilk from a person who has been exposed
  • Ingesting dust or dirt
  • Hand-to-mouth behaviors with textiles treated with stain protectants

ATSDR also notes that some PFAS cross the placenta and enter umbilical cord blood, so exposure can begin before birth. Prenatal timing matters in environmental epidemiology for reasons covered in more depth in prenatal exposure to environmental contaminants.

It is important to read the breastmilk route in context. The same ATSDR guidance states that breastfeeding is optimal due to its many benefits. Naming a route of exposure is not the same as weighing it against everything else that route provides.

What has research associated with PFAS exposure?

ATSDR summarizes the epidemiological evidence as suggesting associations between increases in exposure to specific PFAS and certain health effects. Each outcome is tied to particular compounds, not to PFAS as a single substance (ATSDR, 2024):

Health effectCompounds named by ATSDR
Increases in cholesterol levelsPFOA, PFOS, PFNA, PFDA
Small decreases in birth weightPFOA, PFOS
Lower antibody response to some vaccinesPFOA, PFOS, PFHxS, PFDA
Kidney and testicular cancerPFOA
Pregnancy-induced hypertension or preeclampsiaPFOA, PFOS
Changes in liver enzymesPFOA, PFOS, PFHxS

Two features of this list deserve attention. First, the word is "associations." An association means that, across groups of people, higher measured exposure tends to go along with a higher or lower level of an outcome. It does not by itself establish that the exposure caused the outcome, a distinction explained in detail in work on correlation, causation, and confounding.

Second, the list is compound by compound. With thousands of PFAS in existence and only a few studied, a finding for PFOA says little about a newer substitute compound. ATSDR notes that population exposures to substitute PFAS, such as GenX, are not well studied.

ATSDR also states that the risk of health effects depends on exposure factors such as dose, frequency, route, and duration; on individual factors such as sensitivity and chronic disease burden; and on other determinants of health, such as access to safer water and quality healthcare.

How strong is the evidence on children's immune response?

Immune effects in children are a useful case for learning how to read a body of evidence, because careful sources describe it differently.

ATSDR lists lower antibody response to some vaccines as an association with PFOA, PFOS, PFHxS, and PFDA. An antibody titer is a laboratory measure of how much of a specific antibody is present in the blood, and it is often used to gauge the response to a vaccine.

A 2024 systematic review and meta-analysis by Antoniou and Dekant in Systematic Reviews took a narrower view (Antoniou and Dekant, 2024). A systematic review gathers every eligible study on a question using a predefined search; a meta-analysis then pools their results statistically. This review included 17 studies, 15 birth cohorts and 2 cross-sectional studies, from a PubMed search run until February 1, 2023. Its authors reported:

  • Suggestive evidence for infections, mainly in relation to PFOS, PFOA, PFHxS, and PFNA
  • Moderate to no evidence for a reduction in antibody titers, with very small reported reductions
  • An overall conclusion that the epidemiological evidence does not strongly support an association between PFAS exposure and immune conditions or infectious diseases, along with a call for more research

The review excluded asthma and allergy outcomes, so it draws no conclusions about them.

Three reading skills apply here.

Exposure era. The authors note that many of the associations came from cohorts examined between 1997 and 2009, when exposures were higher than in current populations. ATSDR separately reports that PFOS, PFOA, and PFHxS exposure is decreasing in the US population, in part because of production phase-outs. Findings from a higher-exposure era may not translate directly to today's levels, in either direction.

Small effects and few comparisons. A pooled estimate built on very few comparisons is fragile. Small effect sizes are also where the difference between relative and absolute risk matters most.

Funding disclosures. The review states that both authors received compensation from 3M and that 3M funded portions of the research; the article notes the company previously manufactured products containing PFOA and PFOS chemistries. A disclosure is information for the reader, not a verdict on the work. The appropriate response is neither to dismiss the review nor to accept it uncritically, but to read its methods and compare it with independent summaries such as ATSDR's.

What does a cancer classification mean, and what does it not mean?

In December 2023, the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified PFOA as carcinogenic to humans (Group 1) and PFOS as possibly carcinogenic to humans (Group 2B) (IARC, December 1, 2023).

The basis for each matters:

  • PFOA: sufficient evidence for cancer in experimental animals and strong mechanistic evidence in exposed humans, with limited evidence for cancer in humans (renal cell carcinoma and testicular cancer).
  • PFOS: strong mechanistic evidence across test systems, with inadequate evidence regarding cancer in humans.

IARC is explicit that its classification indicates the strength of the evidence that a substance can cause cancer and does not indicate the level of cancer risk. This is the difference between hazard and risk. Hazard asks whether something can cause harm under some circumstances. Risk asks how likely harm is at a particular level and pattern of exposure. A Group 1 classification is a statement about the first question, not the second.

What can a PFAS blood test tell, and what can it not?

Blood testing is a form of biomonitoring, measuring a chemical or its byproducts directly in the body. The general principles, and their limits, are covered in how scientists measure exposure in children. For PFAS specifically, ATSDR lists what results can and cannot show (ATSDR, 2024):

  • Results reflect current levels in the blood, which could represent recent exposure or, for long-lived compounds, past exposure.
  • Results do not identify the sources of exposure.
  • Results do not indicate whether a current illness can be attributed to PFAS exposure, and do not predict future health problems.
  • Comparing results across laboratories can be difficult.
  • ATSDR has not developed health-based screening blood levels for PFAS.
  • No approved medical treatments are available to remove PFAS from the body.

In 2022, the National Academies of Sciences, Engineering, and Medicine published a consensus report, Guidance on PFAS Exposure, Testing, and Clinical Follow-Up, which recommends that clinicians offer blood testing to people likely to have had high past exposure, such as some workers and residents of contaminated areas. Decisions about testing belong in a conversation with a clinician who knows the individual's history.

Frequently asked questions

Are all PFAS equally studied?

No. ATSDR describes PFAS as a family of thousands of chemicals, of which relatively few have been studied for their effects on health.

Is PFAS exposure going down?

For PFOS, PFOA, and PFHxS, ATSDR reports that exposure in the US population is decreasing, in part because of production phase-outs. Exposure to substitute compounds is not well studied.

Does a higher blood level mean a child will get sick?

No single result can say that. ATSDR states that blood test results do not predict future health problems and do not show whether a current illness can be attributed to PFAS.

PFAS research sits within a broader field studying how environmental exposures relate to child development, the subject of the research hub on autism and the environment. For peer-reviewed work in that area, see the publications page.

About the author. Dr. Manouchehr Hessabi is a physician-epidemiologist and Senior Research Scientist at the BERD core of UTHealth Houston's Center for Clinical and Translational Sciences. See his peer-reviewed publications or research programs.